AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 271 min read$CORT

Maduck Sean sold $3.9M of CORT

Maduck Sean (See Remarks) sold 30,955 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $125.58 ($125.47–$126.06, $3.89M total) across 2 trades on 2026-08-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Maduck Sean
Published Aug 27, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The transaction is a routine insider sale; limited trading relevance.

02

Market read

Small‑scale insider sale; unlikely to affect stock price significantly.

03

What to watch

Potential upcoming clinical trial results or regulatory news not disclosed here.

Relevance 5/10Novelty 4/10Timing: post‑market 2026‑08‑25

Background

Form 4 filing provides the first public disclosure of the insider transaction.

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

Officer Maduck Sean sold 30,955 shares for $3.9M via a 10b5‑1 plan on 2026‑08‑25.

Expected impact

Potential slight downward pressure; unlikely to move price materially.

Evidence & confidence

Sale amount is under $5M and represents a small fraction of total shares; market may view it as routine.

Market effects

Sector

Minimal impact on the pharmaceutical sector; insider sales are common.

Regional

No regional effect.

Global

Not globally relevant.

Counterpoint

What could challenge this read

The sale could be a portfolio rebalancing unrelated to company fundamentals.

Key entities

  • Company
    Corcept Therapeutics Inc

    Biopharmaceutical company developing cortisol‑targeting therapies.

  • Officer
    Maduck Sean

    Company officer who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CORT insider trading history →

Related articles

OCT 26
$CORTHighAI 8/10

Why is Corcept Therapeutics stock rallying today?

Corcept Therapeutics (CORT) stock rose 3.7% in pre-market trading after reporting positive Phase 2 BELLA trial results for Lifyorli in combination with nab-paclitaxel and bevacizumab in platinum-resistant ovarian cancer. The study showed improved median progression-free survival (7.2 months) and objective response rate (59%) compared to the two-drug combination. The stock had previously declined 29.6% due to competitive concerns from Genmab's trial results.

investing.com2 min
OCT 23
$CORTHighAI 8/10

Corcept Therapeutics (CORT) Shares Drop 20% on Genmab's Phase 3

Corcept Therapeutics (CORT) shares dropped 20% to $85.86 after Genmab's phase 3 trial for a competing ovarian cancer drug succeeded, raising concerns about market competition. CORT's GF Value™ suggests it is 11.2% overvalued, while its GF Score™ is 85/100, indicating strong financial health. Insiders have sold $101.5M in shares over the past year, signaling caution.

gurufocus.com3 min
OCT 23
$CORTHighAI 8/10

Why is Corcept Therapeutics stock tumbling today?

Corcept Therapeutics (CORT) shares fell 12.9% after Genmab's rival drug showed positive results in a Phase 3 trial for platinum-resistant ovarian cancer, directly competing with Corcept's Lifyorli. The decline was exacerbated by prior downgrades and market headwinds, with shares dropping from $106.05 to a low of $90.99 before partially recovering to $93.68.

investing.com2 min
SEP 22
$CORTHighAI 8/10

Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle

Corcept Therapeutics (CORT) announced that Europe's drug regulator recommended approval for its cancer therapy, relacorilant, for use with chemotherapy in platinum-resistant ovarian cancer. The recommendation is based on a Phase 3 trial showing improved patient outcomes. The European Commission's final decision is expected in Q4 2026. Corcept reported $47.6M in Q2 revenue from Lifyorli (relacorilant) and raised its full-year revenue guidance to $1.1B-$1.2B, with net income increasing to $43M.

insidermonkey.com3 min